AveXis (NASDAQ:AVXS) had its target price raised by Barclays from $124.00 to $152.00 in a report released on Friday. They currently have an overweight rating on the stock.

AVXS has been the subject of several other reports. Royal Bank of Canada reaffirmed a hold rating and set a $92.00 price objective on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity began coverage on AveXis in a report on Thursday, October 26th. They set a hold rating and a $110.00 price objective for the company. Zacks Investment Research cut AveXis from a buy rating to a hold rating in a report on Monday, October 30th. BidaskClub raised AveXis from a sell rating to a hold rating in a report on Thursday, December 21st. Finally, Chardan Capital reaffirmed a buy rating and set a $135.00 price objective on shares of AveXis in a report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. AveXis presently has an average rating of Buy and an average target price of $116.95.

AveXis (NASDAQ AVXS) opened at $111.90 on Friday. The stock has a market capitalization of $4,020.00 and a price-to-earnings ratio of -20.05. AveXis has a 1-year low of $53.94 and a 1-year high of $128.00.

In other news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Friday, December 1st. The stock was sold at an average price of $94.73, for a total value of $1,420,950.00. Following the completion of the sale, the insider now owns 1,826,502 shares of the company’s stock, valued at $173,024,534.46. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Andrew F. Knudten sold 2,000 shares of AveXis stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $118.13, for a total value of $236,260.00. Following the completion of the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $826,910. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,560 shares of company stock valued at $6,160,062. Insiders own 18.60% of the company’s stock.

Large investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of AveXis in the third quarter valued at $116,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after purchasing an additional 453 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in shares of AveXis in the third quarter valued at $200,000. 81.52% of the stock is owned by institutional investors and hedge funds.

WARNING: “AveXis (AVXS) Price Target Raised to $152.00” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/avexis-avxs-price-target-raised-to-152-00/1862220.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.